Abstract
Neuroendocrine neoplasms (NEN) of the stomach include a heterogeneous group of neoplasms characterized by different pathogenetic mechanisms, metastatic potential, and prognosis. The incidence of gastric NAN has increased 15-fold over the past few decades. It is necessary to clearly distinguish between well-differentiated neuroendocrine neoplasms (NETs) of the stomach and neuroendocrine cancer (NECs) of the stomach, as well as mixed neuroendocrine-non-neuroendocrine neoplasms.
To date, there are three classifications that are used in clinical practice: clinicopathological classification, WHO classification, and UICC TNM classification. It should be noted that over the past five years, these classifications have undergone important changes. In the clinicopathological classification, in addition to the existing three types, a number of authors proposed to add the 4th type (developing as a result of inadequate functioning of the proton pump) and the 5th type (developing in patients who receive long-term therapy with proton pump inhibitors). In the 2019 WHO classification, an important change is the acceptance that well-differentiated NETs can have a high degree of malignancy – Grade III. The main changes in the 8th edition of the TNM classification concerned the differentiation of the M symbol.
Thus, to date, the classification of gastric NENs allows us to accurately characterize tumor staging, the pathogenesis underlying their development, and prognosis. They form the basis for choosing an adequate treatment strategy that makes possible to achieve the most favourable result.
References
Dasari A, Shen C, Halperin D et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States // JAMA Oncol. 2017;3(10):1335–1342. https://doi:10.1001/jamaoncol.2017.0589
Jesinghaus M, Konukiewitz B, Keller G et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas // Mod Pathol. 2017;30(4):610–619. https://doi:10.1038/modpathol.2016.220
Uccella S, La Rosa S. Looking into digestive mixed neuroendocrine — nonneuroendocrine neoplasms: subtypes, prognosis, and predictive factors // Histopathology. 2020;77(5):700–717. https://doi:10.1111/his.14178
Перегородиев И.Н., Бохян В.Ю., Делекторская В.В., Стилиди И.С. Нейроэндокринные опухоли желудка. Современная классификация // Российский онкологический журнал. 2016;21:81–85. https://doi:10.18821/1028-9984-2016-21-1-81-85 [Peregorodiev I.N., Bokhian V.Y., Delektorskaya V.V., Stilidi I.S. Neuroendocrine tumors of stomach. Modern classification // Russian Journal of Oncology. 2016;21:81–85 (in Russ.)]. https://doi:10.18821/1028-9984-2016-21-1-81-85
Carney JA, Go VL, Fairbanks VF et al. The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy // Ann Intern Med. 1983;99(6):761–766 https://doi:10.7326/0003-4819-99-6-761
Rindi G, Luinetti O, Cornaggia M et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study // Gastroenterology. 1993;104(4):994–1006. https://doi:10.1016/0016-5085(93)90266-f
Bordi C. Neuroendocrine pathology of the stomach: the Parma contribution // Endocr Pathol. 2014;25(2):171–180. https://doi:10.1007/s12022-014-9315-x
La Rosa S, Rindi G, Solcia E, Tang L. Gastric neuroendocrine neoplasms. WHO classification of tumors digestive system tumors. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC), 2019:104–109.
Bordi C, Yu JY, Baggi MT et al. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases // Cancer. 1991;67(3):663–672. https://doi:10.1002/1097-0142(19910201)67:3<663::aid-cncr2820670323>3.0.co;2-l
Oksanen A, Sipponen P, Karttunen R et al. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy // Gut. 2000;46(4):460–463. https://doi:10.1136/gut.46.4.460
Sato Y, Iwafuchi M, Ueki J et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection // Dig Dis Sci. 2002;47(3):579–585. https://doi:10.1023/a:1017972204219
Berna MJ, Annibale B, Marignani M et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors // J Clin Endocrinol Metab. 2008;93(5):1582–1591. https://doi:10.1210/jc.2007-2279
Borch K, Ahrén B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type // Ann Surg. 2005;242(1):64–73. https://doi:10.1097/01.sla.0000167862.52309.7d
La Rosa S, Inzani F, Vanoli A et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms // Hum Pathol. 2011;42(10):1373–1384. https://doi:10.1016/j.humpath.2011.01.018
Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours // Digestion. 1995;56(6):455–462. https://doi:10.1159/000201276
Rindi G, Azzoni C, La Rosa S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis // Gastroenterology. 1999;116(3):532–542. https://doi:10.1016/s0016-5085(99)70174-5
Vanoli A, La Rosa S, Miceli E et al. Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up // Neuroendocrinology. 2018;107(2):114–126. https://doi:10.1159/000489902
https://doi:www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
Delle Fave GF, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage J, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; all other Vienna Consensus Conference participants.
https://doi:www.annalsofoncology.org/article/S0923-7534(20)36394-8/fulltext
La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions // J Clin Pathol. 2014;67(11):938–948. https://doi:10.1136/jclinpath-2014-202515
Ooi A, Ota M, Katsuda S et al. An Unusual Case of Multiple Gastric Carcinoids Associated with Diffuse Endocrine Cell Hyperplasia and Parietal Cell Hypertrophy // Endocr Pathol. 1995;6(3):229–237. https://doi:10.1007/BF02739887
Abraham SC, Carney JA, Ooi A et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder // Am J Surg Pathol. 2005;29(7):969–975. https://doi:10.1097/01.pas.0000163363.86099.9f
Fossmark R, Calvete O, Mjønes P et al. ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPase alpha subunit // APMIS. 2016;124(7):561–566. https://doi:10.1111/apm.12546
Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis // Histopathology. 2020;77(6):865–876. https://doi:10.1111/his.14220
Lee HE, Mounajjed T, Erickson LA, Wu TT. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index // Endocr Pathol. 2016;27(3):259–267. https://doi:10.1007/s12022-016-9443-6
La Rosa S, Solcia E. New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia // Histopathology. 2020;77(6):862–864. https://doi:10.1111/his.14226
WHO Classification of Tumours Editorial Board, eds. WHO Classification of Tumors: Digestive System Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2019. World Health Organization Classification of Tumours; vol 1.
Rindi G, Klimstra DS, Abedi-Ardekani B et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal // Mod Pathol. 2018;31(12):1770–1786. https://doi:10.1038/s41379-018-0110-y
Rindi G, Arnold R, Bosman FT et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F.T. et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010:13–4.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021